Some are questioning whether Mylan's generic EpiPen may net the drugmaker more revenue than the original version. » Read More
Jim Cramer said Monday price adjustments from EpiPen's owner Mylan can be attributed to the rise of vocal social media platforms such as Twitter. » Read More
There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC. » Read More
People with three or more chronic illnesses and functional limitations tend to be poorer and older. » Read More
Get the best of CNBC in your inbox
Dan Mangan is a reporter covering health care for CNBC.com.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.
Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.